Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND
Authors' conclusion
Over three-quarters of bDMARD-IR patients achieved CDAI LDA with upadacitinib, and almost half of those maintained LDA through 240 weeks of follow-up. Remission was achieved by nearly half of all patients and maintained in approximately a quarter of those achieving remission.
Study context
- Population
- bDMARD-IR patients with active RA on background csDMARDs
- Comparison
- Upadacitinib 15 mg once daily on background csDMARDs; sustainability of response
- Primary endpoint
- Sustainability of response: achievement of CDAI, SDAI and DAS28-CRP targets
- Follow-up
- Up to week 260
Methodological detailslong-term extension up to 5 years, placebo-controlled (switch from placebo to upadacitinib 15 mg at week 12)
- Long-term extension up to 5 years
- Placebo-controlled (switch from placebo to upadacitinib 15 mg at week 12)
Primary result
As reported in the abstract
Clinical Disease Activity Index (CDAI) remission achieved at any point (n=104/229)
45%
CDAI low disease activity (LDA) achieved at any point (n=172/219)
79%
Maintained initial CDAI remission through 240 weeks after first response
25%
Maintained initial CDAI LDA through 240 weeks after first response
43%
Further findings
Simplified Disease Activity Index (SDAI) and DAS28-CRP targets
- Similar overall results to CDAI
Predictors of response
- No strong predictors of response identified
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →